| NCT ID | NCT02292641 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imperial College London |
| Condition | Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 383 participants |
| Start Date | 2014-09-25 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 383 participants in total. It began in 2014-09-25 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.
Eligibility Criteria
Inclusion Criteria: 1. Had a primary colorectal adenocarcinoma proven by biopsy taken as part of routine clinical practice 2. Has a confirmed diagnosis of recurrent pelvic colorectal cancer 3. Has previously completed surgical treatment of primary adenocarcinoma of the colon, sigmoid colon or rectum 4. Are able to undergo high resolution MRI for staging prior to treatment decisions 5. Have provided written informed consent to participate in the study 6. Be aged 16 years or over Exclusion Criteria: 1. Have irresectable extra-pelvic metastatic disease 2. Original baseline staging and preoperative restaging scans (MR for rectal and sigmoid cancers and/or CT for colon and sigmoid cancers) are unavailable 3. Original preoperative, surgical and adjuvant treatment has not been documented or is unavailable
Contact & Investigator
Gina Dr Brown, MD
PRINCIPAL INVESTIGATOR
Imperial College London
Frequently Asked Questions
Who can join the NCT02292641 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02292641 currently recruiting?
Yes, NCT02292641 is actively recruiting participants. Contact the research team at c.martin1@imperial.ac.uk for enrollment information.
Where is the NCT02292641 trial being conducted?
This trial is being conducted at Oslo, Norway, Harrow, United Kingdom, Oxford, United Kingdom, Sutton, United Kingdom.
Who is sponsoring the NCT02292641 clinical trial?
NCT02292641 is sponsored by Imperial College London. The principal investigator is Gina Dr Brown, MD at Imperial College London. The trial plans to enroll 383 participants.